Kanger gets biotechnology board's greenlight on China Covid-19 vaccine
Published: Nov 23, 2020 8:40 AM | Updated: Nov 23, 2020 10:49 AM
COVID-19 | Kanger International Berhad announced that the National Institutes of Biotechnology Malaysia (NIBM) has issued a letter stating it has no objections for the company to communicate with Sinopharm to purchase Covid-19 vaccines for private sector use in Malaysia.
This followed Kanger’s announcement on Sept 29 that the group, which is chaired by former deputy minister Nur Jazlan Mohamed, entered into a three-year collaboration agreement with Sinopharm Group Hunan Changde Medical Co Ltd.
The deal is for the distribution of Covid-19 vaccines and medical equipment in Malaysia developed by China National Pharmaceutical Group Corporation (Sinopharm)...
View Comments0
Report this comment
500 characters remaining
Are you sure you want to delete this comment?
This action cannot be undone.